RU2021113126A - Средства для лечения инфекции вируса гепатита в (hbv) и их применение - Google Patents
Средства для лечения инфекции вируса гепатита в (hbv) и их применение Download PDFInfo
- Publication number
- RU2021113126A RU2021113126A RU2021113126A RU2021113126A RU2021113126A RU 2021113126 A RU2021113126 A RU 2021113126A RU 2021113126 A RU2021113126 A RU 2021113126A RU 2021113126 A RU2021113126 A RU 2021113126A RU 2021113126 A RU2021113126 A RU 2021113126A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- seq
- nucleic acid
- effector
- shmir
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims 11
- 208000015181 infectious disease Diseases 0.000 title claims 8
- 239000003814 drug Substances 0.000 title claims 3
- 229940079593 drug Drugs 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 claims 56
- 150000007523 nucleic acids Chemical class 0.000 claims 56
- 102000039446 nucleic acids Human genes 0.000 claims 56
- 239000012636 effector Substances 0.000 claims 39
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 32
- 230000000295 complement effect Effects 0.000 claims 25
- 239000013604 expression vector Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 12
- 239000002679 microRNA Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 8
- 108091027967 Small hairpin RNA Proteins 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108020005065 3' Flanking Region Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 229960001997 adefovir Drugs 0.000 claims 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
- 229960000980 entecavir Drugs 0.000 claims 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 229960004556 tenofovir Drugs 0.000 claims 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108020005029 5' Flanking Region Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332245P | 2016-05-05 | 2016-05-05 | |
| US62/332,245 | 2016-05-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142797A Division RU2748806C2 (ru) | 2016-05-05 | 2017-05-05 | Средства для лечения инфекции вируса гепатита в (hbv) и их применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2021113126A true RU2021113126A (ru) | 2021-08-20 |
Family
ID=60202535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142797A RU2748806C2 (ru) | 2016-05-05 | 2017-05-05 | Средства для лечения инфекции вируса гепатита в (hbv) и их применение |
| RU2021113126A RU2021113126A (ru) | 2016-05-05 | 2017-05-05 | Средства для лечения инфекции вируса гепатита в (hbv) и их применение |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142797A RU2748806C2 (ru) | 2016-05-05 | 2017-05-05 | Средства для лечения инфекции вируса гепатита в (hbv) и их применение |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11535851B2 (enExample) |
| EP (1) | EP3452595A4 (enExample) |
| JP (1) | JP2019514401A (enExample) |
| KR (1) | KR102358280B1 (enExample) |
| CN (1) | CN109415733A (enExample) |
| AU (2) | AU2017260580B2 (enExample) |
| CA (1) | CA3023185A1 (enExample) |
| PH (1) | PH12018502320A1 (enExample) |
| RU (2) | RU2748806C2 (enExample) |
| SG (1) | SG11201809753YA (enExample) |
| WO (1) | WO2017190197A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3452595A4 (en) * | 2016-05-05 | 2020-02-19 | Benitec Biopharma Limited | REAGENTS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF |
| JP7441174B2 (ja) * | 2018-11-16 | 2024-02-29 | 公益財団法人東京都医学総合研究所 | Ｂ型肝炎ウイルスの複製阻害組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| RU2217161C2 (ru) * | 1997-08-26 | 2003-11-27 | Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) | Способ лечения вирусного гепатита |
| JP4210737B2 (ja) * | 2001-07-12 | 2009-01-21 | ユニバーシティー オブ マサチューセッツ | 遺伝子サイレンシングを仲介する低分子干渉リボ核酸のインビボにおける製造方法 |
| CN1257284C (zh) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| US8575327B2 (en) * | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| AU2005319306B9 (en) | 2004-12-22 | 2012-04-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| WO2008147430A2 (en) * | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| CN101603042B (zh) * | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| US20120142764A1 (en) * | 2009-06-05 | 2012-06-07 | Dai-Wu Seol | Multi-Cistronic shRNA Expression Cassette for Suppressing Single or Multiple Target Genes |
| US20130267429A1 (en) * | 2009-12-21 | 2013-10-10 | Lawrence Livermore National Security, Llc | Biological sample target classification, detection and selection methods, and related arrays and oligonucleotide probes |
| KR20180110186A (ko) | 2010-10-28 | 2018-10-08 | 베니텍 바이오파마 리미티드 | Hbv 치료 |
| KR102434346B1 (ko) * | 2011-06-30 | 2022-08-18 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| HRP20220607T1 (hr) * | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| WO2014117050A2 (en) * | 2013-01-26 | 2014-07-31 | Mirimus, Inc. | Modified mirna as a scaffold for shrna |
| CN103088026A (zh) | 2013-02-01 | 2013-05-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 抗乙型肝炎病毒人工miRNA及其组合 |
| PL243776B1 (pl) * | 2013-09-02 | 2023-10-09 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Cząsteczka kwasu nukleinowego, kaseta ekspresyjna, wektor ekspresyjny, komórka eukariotycznego gospodarza i zastosowanie cząsteczki kwasu nukleinowego w terapii chorób wywoływanych ekspansją trójnukleotydowych powtórzeń typu CAG |
| SG11201708679YA (en) * | 2015-05-06 | 2017-11-29 | Benitec Biopharma Ltd | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
| EP3452595A4 (en) * | 2016-05-05 | 2020-02-19 | Benitec Biopharma Limited | REAGENTS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF |
-
2017
- 2017-05-05 EP EP17792296.0A patent/EP3452595A4/en not_active Withdrawn
- 2017-05-05 KR KR1020187035341A patent/KR102358280B1/ko not_active Expired - Fee Related
- 2017-05-05 CN CN201780040430.8A patent/CN109415733A/zh active Pending
- 2017-05-05 AU AU2017260580A patent/AU2017260580B2/en not_active Ceased
- 2017-05-05 CA CA3023185A patent/CA3023185A1/en active Pending
- 2017-05-05 US US16/098,759 patent/US11535851B2/en active Active
- 2017-05-05 RU RU2018142797A patent/RU2748806C2/ru active
- 2017-05-05 SG SG11201809753YA patent/SG11201809753YA/en unknown
- 2017-05-05 WO PCT/AU2017/050413 patent/WO2017190197A1/en not_active Ceased
- 2017-05-05 JP JP2018557875A patent/JP2019514401A/ja active Pending
- 2017-05-05 RU RU2021113126A patent/RU2021113126A/ru unknown
-
2018
- 2018-11-05 PH PH12018502320A patent/PH12018502320A1/en unknown
-
2022
- 2022-09-27 AU AU2022241489A patent/AU2022241489A1/en not_active Abandoned
- 2022-11-18 US US18/056,929 patent/US20230093951A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017260580A1 (en) | 2018-11-22 |
| US20190338285A1 (en) | 2019-11-07 |
| RU2018142797A (ru) | 2020-06-05 |
| US11535851B2 (en) | 2022-12-27 |
| KR102358280B1 (ko) | 2022-02-07 |
| AU2022241489A1 (en) | 2022-10-20 |
| CA3023185A1 (en) | 2017-11-09 |
| RU2748806C2 (ru) | 2021-05-31 |
| US20230093951A1 (en) | 2023-03-30 |
| PH12018502320A1 (en) | 2022-01-24 |
| EP3452595A1 (en) | 2019-03-13 |
| SG11201809753YA (en) | 2018-12-28 |
| KR20190003756A (ko) | 2019-01-09 |
| WO2017190197A1 (en) | 2017-11-09 |
| EP3452595A4 (en) | 2020-02-19 |
| AU2017260580B2 (en) | 2022-07-28 |
| RU2018142797A3 (enExample) | 2020-09-10 |
| JP2019514401A (ja) | 2019-06-06 |
| CN109415733A (zh) | 2019-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kang et al. | Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges | |
| AU2022205929B2 (en) | RNAi agents for Hepatitis B virus infection | |
| JP2005521393A5 (enExample) | ||
| RU2013124422A (ru) | Лечение hbv-инфекции | |
| JP2016522674A5 (enExample) | ||
| JP2015518713A5 (enExample) | ||
| RU2020108189A (ru) | Композиции и способы лечения бокового амиотрофического склероза (als) | |
| JP2015518712A5 (enExample) | ||
| RU2015133252A (ru) | Лечение возрастной макулярной дегенерации | |
| JP2015523855A5 (enExample) | ||
| JP2019508045A5 (enExample) | ||
| WO2017050836A1 (en) | Antisense oligonucleotides and uses thereof | |
| RU2018137677A (ru) | Модифицированная промоторная система u6 для тканеспецифической экспрессии | |
| RU2021113126A (ru) | Средства для лечения инфекции вируса гепатита в (hbv) и их применение | |
| JP2020503014A5 (enExample) | ||
| JP2020527167A5 (enExample) | ||
| CN114729354A (zh) | 炎性相关疾病防治的小rna药物及其组合 | |
| JP2019514401A5 (enExample) | ||
| EP4329761A1 (en) | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment | |
| JP2019513395A5 (enExample) | ||
| RU2018138271A (ru) | Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение | |
| Zhang et al. | Antisense oligonucleotides targeting the RNA binding region of the NP gene inhibit replication of highly pathogenic avian influenza virus H5N1 | |
| CN110891603A (zh) | 用于治疗肠道病毒感染的组合物和方法 | |
| EA200500873A1 (ru) | Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита | |
| JP2008503569A5 (enExample) |